[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"appendiceal-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:appendiceal-adenocarcinoma":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,76,112,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100641183","phase-1-tlr9-immunotherapy-for-peritoneal-carcinomatosis-100641183",false,"NCT07658196","TLR9 Immunotherapy for Peritoneal Carcinomatosis","TLR9 Immunotherapy for Peritoneal Carcinomatosis (TIPC) - Phase 1 Study of the Safety and Efficacy of ACM-CpG Intraperitoneal Injections for Treatment in Patients With Colorectal or Appendiceal Adenocarcinoma Peritoneal Metastases or Malignant Ascites","TIPC","Inclusion Criteria:\n\n* Patients eligible for inclusion in this study must meet all of the following criteria:\n\n  1. Male or female patients age ≥ 18 years of age at the time of informed consent\n  2. Must be able to provide written informed consent, stating an understanding of the procedures and investigational nature of the study treatment, and willingness to comply with study requirements\n  3. Must have documented CRC or appendiceal adenocarcinoma peritoneal carcinomatosis or malignant ascites. Primary tumor may be intact and limited liver and\u002For lung disease is permitted\n  4. Must have evaluable disease by physical examination, serum tumor markers, radiologic assessment, or laparoscopic visual assessment\n  5. Must have a life expectancy of ≥ 12 weeks as estimated by the investigator\n  6. Must have an ECOG status of ≤ 2\n  7. Patients with acceptable laboratory values defined as:\n\n     * Estimated creatinine clearance (calculated using Cockcroft-Gault formula, or measured) ≥ 60 mL\u002Fmin, not dialysis dependent\n     * Total bilirubin ≤ 1.5 mg\u002Fdl, unless elevated bilirubin is clearly related to Gilbert syndrome (and total bilirubin \\\u003C 6.0 mg\u002Fdl)\n     * Alanine aminotransferase (ALT) ≤ 3.5 x upper limit of normal (ULN)\n     * Aspartate aminotransferase (AST) ≤ 3.5 x ULN\n     * Absolute neutrophil count \\> 1.0 x 109\u002FL (must be independent of blood product administration)\n     * Platelet count \\> 100 x 109\u002FL (must be independent of blood product administration)\n     * Hemoglobin ≥ 8 g\u002FdL (must be independent of blood product administration)\n  8. Surgically sterile patients or patients of childbearing potential (CBP) who agree to use highly effective methods of contraception during study dosing and for 6 months after last dose of study drug\n  9. All other relevant medical conditions must be well-managed and stable, in the opinion of the investigator, for at least 28 days prior to administration of study drug\n\nExclusion Criteria:\n\n1. Has received prior TLR9 therapy\n2. Has received chemotherapy, radiotherapy, or biological cancer therapy within 21 days or 5 half-lives (whichever is shorter) of the start of treatment\n3. Has received an investigational agent within 28 days of the start of treatment\n4. Has received a commercial vaccine (flu, COVID, etc.) within 2 weeks of C1D1\n5. Has any unresolved toxicity ≥ Grade 2 from previous anti-cancer therapy, except for stable chronic toxicities (≤ Grade 3) that are not expected to resolve\n6. Has a history of histologically confirmed metastases outside of the peritoneal cavity, liver, or lungs\n7. Has high volume liver or lung metastases, defined as \\> 50% replacement of the liver volume by metastatic disease or \\> 5 lung lesions greater than 1 cm in size\n8. Tumor causing biliary obstruction not amenable to stenting or percutaneous drainage\n9. Ongoing or untreated intra-abdominal infection or bowel obstruction\n10. Has known, clinically active Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV) (Note: Testing is not required)\n11. Receiving continuous systemic corticosteroid therapy (≥ 10 mg\u002Fday of prednisolone or equivalent)\n12. Clinically significant cardiac disease or impaired cardiac function, including any of the following:\n\n    * A history of newly diagnosed transmural myocardial infarction, cerebral infarction, or pulmonary embolism within 6 months, except those approved by the medical monitor\n    * A history of newly diagnosed deep vein thrombosis (DVT) within 3 months\n    * Left ventricular ejection fraction (LVEF) \\\u003C 50%\n    * QTc \\>480 msec\n13. Active bacterial, viral, or fungal infection: patients with ongoing use of prophylactic antibiotics, antiviral agents, or antifungal agents remain eligible as long as there is no evidence of active infection\n14. Other active malignancy within 2 years excluding cutaneous squamous or basal cell carcinomas\n15. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results\n16. History of hypersensitivity to TLR9 agonists\n17. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation)","ALL","18 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites. The main questions it aims to answer are:\n\n• To determine the safety and maximum tolerated dose (MTD) or optimal biologic dose (OBD) of intraperitoneal injection(s) of ACM-CpG for inoperable peritoneal metastases or malignant ascites? Researchers will assign treatment levels using escalating doses of ACM-CpG Therapy.\n\nParticipants will:\n\n* Will receive at least one dose of ACM-CpG therapy on Day 1 of a 28-day treatment cycle.\n* May receive up to 2 additional injections if they have clinically stable or responsive disease.\n* Must visit the clinic on Days 1, 4, 7, 10, 14, 21, and 28 for checkups and tests.\n* Will have a CT scan or MRI performed every 8 weeks for 3 scans and then continue to receive scans every 12 weeks to monitor their disease.",[27,28,29,30],"Malignant Ascites","Colorectal Adenocarcinoma","Peritoneal (Metastatic) Cancer","Appendiceal Adenocarcinoma",[32,33,34,27,35,30,36],"Metastatic disease must be primarily located in the peritoneal cavity","ACM-CpG","TLR9","Peritoneal Carcinomatosis,","CRC","NOT_YET_RECRUITING","2026-08-19",{"date":40,"type":41},"2026-08-20","ACTUAL",{"date":43,"type":21},"2026-08",{"date":45,"type":21},"2030-07",{"name":47,"class":48},"Brown University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":49},"100650909","a-phase-ii-study-of-ivonescimab-combined-with-intraperitoneal-paclitaxel-in-patients-with-high-grade-metastatic-appendiceal-adenocarcinoma-aa-100650909","NCT07753824","A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)","Inclusion Criteria\n\n* Age 18 years and above. There will be no upper age restriction\n* ECOG performance status 0-2\n* Participants must have histologically confirmed diagnosis of unresectable metastatic AA. The determination of appendiceal origin may rely on pathologic features combined with clinical or radiographic evidence in the event that the appendix remains in situ.\n* Participants will have undergone no more than two prior lines of systemic therapy. The last dose of systemic therapy will have been no less than 2 weeks prior to initiation of therapy.\n* Participants must have adequate nutrition and normal bowel motility and function as evidenced by albumin \\> 3.0 and no history of intestinal bypass or diverting enterostomy.\n* Demonstrate adequate organ function as determined by the following requirements:\n\n  o Hematology\n* No use of any blood components and cell growth factor supportive therapy within 7 days prior to initiation of study treatment\n* Absolute neutrophil count (ANC) ≥ 1,500\u002Fmm3 (ANC ≥ 1000\u002Fmm3 for African American participants)\n* Platelet count ≥ 100 × 109\u002FL (100,000\u002Fmm3)\n* Hemoglobin ≥ 9.0 g\u002FdL.\n\n  o Kidney:\n* Creatinine clearance\\* (CrCL) ≥ 50 mL\u002Fmin using the Cockcroft-Gault formula or estimated glomerular filtration rate (eGFR) value ≥50 mL\u002Fmin using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (adjustment by body surface area \\[BSA\\] is not required for eGFR). \\*CrCL or eGFR can be determined using the calculator from the National Kidney Foundation website (www.kidney.org).\n* Urine protein \\\u003C 2+ or 24-hour urine protein quantification \\\u003C 1.0 g\n\n  o Liver:\n* Serum total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); for participants with confirmed\u002Fsuspected Gilbert syndrome, TBIL ≤3 x ULN\n* Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ULN\n* Coagulation: prothrombin time (PT) or international normalized ratio (INR) ≤ 1.5 × ULN, and partial thromboplastic time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (unless abnormalities are unrelated to coagulopathy). This applies only to participants who are not on therapeutic anti-coagulation. Participants receiving therapeutic anti-coagulation should be on a stable dose\n* The effects of PTX and Ivonescimab on the developing human fetus are unknown. Taxane agents are known to be teratogenic. Additionally, based on Ivonescimab's mechanism of action, it may cause fetal harm if administered to a pregnant woman. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation until 6 months after the last dose of Ivonescimab. (Refer to Pregnancy Assessment Policy UT MD Anderson Institutional Policy # CLN1114). This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the participant presents with an applicable exclusionary factor which may be one of the following:\n\n  * Postmenopausal (no menses in greater than or equal to 12 consecutive months)\n  * History of hysterectomy or bilateral salpingo-oophorectomy\n  * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy)\n  * History of bilateral tubal ligation or another surgical sterilization procedure\n* Approved methods of birth control are as follows: Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Unsterilized male participants having sex with a female partner of childbearing potential, or a pregnant or breastfeeding partner must agree to use barrier contraception (male condom) for the duration of the treatment period until 6 months after last dose of Ivonescimab or chemotherapy. Male participants with female partners of childbearing potential must have the female partner agree to use at least 1 form of highly effective contraception for the duration of treatment period until 6 months after last dose of Ivonescimab.\n* Female participants of childbearing age must have a negative serum pregnancy test result before enrollment and a negative urine pregnancy test on the day of first dose prior to dosing.\n* Ability to understand and the willingness to sign a written informed consent document\n* Participants with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n\nExclusion Criteria\n\n* Metastases outside the peritoneal cavity, with exception of limited metastases to the thoracic cavity and\u002For limited retroperitoneal lymphadenopathy\n* Previous surgery that would preclude safe diagnostic laparoscopy with port placement\n* Current presence of significant radiographic or clinical\u002Fradiographic manifestations of gastrointestinal obstruction. History of perforation of the gastrointestinal tract and\u002For fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to enrollment\n* Recent history (within the last 30 days) of large volume ascites requiring repeated paracenteses. Large-volume ascites that has resolved with prior systemic therapies is not considered Exclusionary.\n* Unresolved clinically significant toxicity of greater than or equal to NCI CTCAE v. 6.0 grade 2 attributed to any prior therapies (excluding anemia, lymphopenia, alopecia, skin pigmentation).\n* Other prior malignancy unless the participant has undergone curative therapy with no evidence of disease recurrence within 3 years prior to enrollment. The following malignancies will be allowed without the 3-year interval after adequate treatment: basal cell or squamous cell carcinoma of skin, superficial bladder cancer, in situ cervical cancer, other in situ cancers, prostate cancer with a Gleason score ≤6 that does not need therapy or other local tumors that are considered cured\n* Concurrent enrollment in another clinical study, unless it is an observational, non-interventional clinical study or a follow-up period for an interventional study.\n* Palliative local therapy for non-target lesions and non-specific immunomodulatory therapy (such as interleukin, interferon, thymus peptide, tumor necrosis factor, etc.) within 2 weeks before the first dose.\n* Any prior clinically significant or active autoimmune disease requiring systemic therapy (e.g., with disease- modifying drugs, prednisone \\>10 mg daily or equivalent, immunosuppressant therapy or immunomodulatory agents \\[e.g., infliximab or IVIG\\]) within 2 years prior to enrollment; however, replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is permitted.\n* History of major diseases before enrollment, specifically:\n\n  * Unstable angina, myocardial infarction, CHF (New York Heart Association \\[NYHA\\] classification ≥Grade 2) or unstable vascular disease (e.g., aortic aneurysm at risk of rupture, Moyamoya disease) that required hospitalization within 12 months prior to enrollment, or other cardiac impairment that may affect the safety evaluation of the study drug (e.g., poorly controlled arrhythmias, myocardial ischemia)\n  * History of esophageal gastric varices, severe ulcers, wounds that do not heal, fistula, intra-abdominal abscesses, or ≥ Grade 3 acute gastrointestinal bleeding within 6 months before enrollment\n  * History of any grade arterial thromboembolic event (ATE), Grade 3 and above venous thromboembolism (VTE), as specified in NCI CTCAE6.0, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 12 months prior to enrollmentAcute exacerbation of chronic obstructive pulmonary disease within 4 weeks before enrollment\n* Live vaccine or live attenuated vaccine within 4 weeks prior to planned enrollment, or if scheduled to receive a live vaccine or live attenuated vaccine during the study period. Inactivated vaccines are permitted.\n* Severe infection within 4 weeks prior to enrolment, including but not limited to comorbidities requiring hospitalization, sepsis, or severe pneumonia; active infection (as determined by the Investigator) requiring systemic anti-infective therapy within 2 weeks prior to enrollment (excluding antiviral therapy for hepatitis B).\n* Major surgical procedures or serious trauma within 4 weeks prior to enrollment or plans for major surgical procedures within 4 weeks after the first dose (as determined by the Investigator). Minor local procedures within 3 days prior to enrollment (excluding central venous catheterization and port implantation).\n* History of bleeding tendencies or coagulopathy and\u002For clinically significant bleeding symptoms or risk within 4 weeks prior to enrollment, including but not limited to:\n\n  * Clinically significant gastrointestinal bleeding such as hematochezia of approximately 1 tablespoon or more per day or any episodes of melena or documented acute hemoglobin drop of more than 1 gm in 2 weeks prior to enrollment\n  * Current use of prophylactic or full-dose anticoagulants or anti-platelet agents for therapeutic purposes that is not stable prior to enrollment is not allowed. The use of fulldose anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits according to the medical standard of the enrolling institution.\n* Poorly controlled hypertension with systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy\n* History of non-infectious pneumonia requiring systemic corticosteroids. History of or current interstitial lung disease\n* Active or prior history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea)\n* Current use of systemic corticosteroids (\\>10 mg daily prednisone or equivalent)\n* Participants with known active tuberculosis (TB) and suspected active TB need to be ruled out by clinical examination.\n* Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n* Known history of human immunodeficiency virus (HIV) whose viral load is not controlled\n* Participants with active hepatitis B are required to have stable or declining levels of hepatitis B virus (HBV) DNA by polymerase chain reaction (PCR) on appropriate anti-viral therapy with acceptable tolerability for 1 month prior to enrollment. All active hepatitis C participants (hepatitis C virus \\[HCV\\] positive with HCV RNA levels above the lower limit of detection) are excluded.\n* Known hypersensitivity to any component of any of the study drugs; known history of severe hypersensitivity reactions to other monoclonal antibodies.\n* History or current evidence of any condition (medical \\[including AEs from prior anti- cancer therapy, disorders secondary to tumor\\], surgical or psychiatric \\[including current substance abuse\\]), or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, might lead to higher medical risk and\u002For is not in the best interest of the participant to participate, in the opinion of the treating Investigator\n* Pregnant women are excluded from this study because both paclitaxel and Ivonescimab have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued.\n* Participant is breastfeeding or plans to breastfeed during the study.\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements",{"count":57,"type":21},30,[59],"PHASE2","To evaluate the safety and effectiveness of Ivonescimab combined with intraperitoneal paclitaxel (IP PTX) in patients with unresectable metastatic high-grade Appendiceal Adenocarcinoma (AA).",[62,63,64,65,66,30],"Phase II","Ivonescimab","Intraperitoneal","Paclitaxel","High Grade Metastatic","2026-08-13",{"date":69,"type":41},"2026-08-17",{"date":71,"type":21},"2027-01-16",{"date":73,"type":21},"2032-11-28",{"name":75,"class":48},"M.D. Anderson Cancer Center",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":49},"100639738","molecular-profiling-for-risk-stratification-in-appendiceal-cancer-100639738","NCT07587268","Molecular Profiling for Risk Stratification in Appendiceal Cancer","Molecular Profiling for Tumor Characterization and Risk Stratification in Patients With Appendiceal Cancer","Inclusion Criteria:\n\n* Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer.\n* Availability of archived tumor tissue suitable for molecular profiling.\n* Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both.\n* Availability of relevant clinicopathologic data.\n* Availability of survival or follow-up information when applicable.\n* Age 18 years or older at diagnosis or tissue collection.\n\nExclusion Criteria:\n\n* Insufficient tissue quantity or quality for molecular profiling.\n* Inadequate DNA or RNA quality for sequencing or molecular assay preparation.\n* Missing essential clinicopathologic information required for analysis.\n* Non-appendiceal primary tumor or metastatic tumor to the appendix from another primary site.\n* Patients who do not meet institutional review board or consent requirements, if applicable.",{"count":84,"type":21},400,"OBSERVATIONAL","This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.",[88,30],"Appendiceal Cancer",[90,91,92,93,94,95,96,97,98,99,100,101],"Appendiceal cancer","Appendiceal adenocarcinoma","DNA methylation","m6A modification","Multi-omics","MeRIP-seq","Histologic grade;","Epigenomics","Epitranscriptomics","Molecular subtype","Risk stratification","Prognostic biomarker","RECRUITING","2026-06-25",{"date":105,"type":41},"2026-06-29",{"date":107,"type":41},"2026-05-01",{"date":109,"type":21},"2027-01-01",{"name":111,"class":48},"City of Hope Medical Center",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":49},"100512083","a-prospective-feasibility-study-using-ctdna-to-tailor-neoadjuvant-chemotherapy-for-patients-with-colorectal-or-appendiceal-adenocarcinoma-100512083","NCT05947838","A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma","Inclusion Criteria:\n\n* Histologically\u002Fcytologically confirmed diagnosis of moderate or poorly differentiated appendiceal or colorectal adenocarcinoma of any grade with Initial resectable disease.\n* Have metastatic peritoneal disease that is visible on imaging or at the time of laparoscopy.\n* Age ≥18 years. Because no adverse event data are currently available on the use of ctDNA in chemotherapy decision making in patients \\\u003C18 years of age, children are excluded from this study.\n* ECOG performance status ≤1 (Karnofsky ≥70%,).\n* Patients must have adequate organ and marrow function as defined below:\n\nabsolute neutrophil count ≥1,000\u002FmcL platelets ≥100,000\u002FmcL total bilirubin 1.5x ≤ institutional upper limit of normal (ULN) AST(SGOT)\u002FALT(SGPT) ≤3 × institutional ULN Creatinine clearance ≥30 mL\u002Fmin\n\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with treated brain metastases are not eligible.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* Estimated life-expectancy of \\> 4 months.\n* The effects of standard chemotherapeutic agents used in this trial (5-fluouracil, oxaliplatin, leucovorin, and irinotecan) on the developing human fetus are detrimental. For this reason and because these agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n\n  * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n  * History of hysterectomy or bilateral salpingo-oophorectomy.\n  * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n  * History of bilateral tubal ligation or another surgical sterilization procedure.\n* Approved methods of birth control are as follows: Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of their chemotherapy administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n* English and Non-English-speaking.\n\nExclusion Criteria:\n\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia.\n* Patients who are receiving any other investigational agents.\n* Patients with brain or other visceral (i.e. liver and\u002For lung) metastases at the discretion of the investigator.\n* Patients with uncontrolled intercurrent illness (Indicate clearly what type or extent)\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because chemotherapeutic agents used carry the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapy, breastfeeding should be discontinued if the mother is treated with chemotherapy. These potential risks may also apply to other agents used in this study.\n* If participant received major surgery within last 4 weeks, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting study treatment.\n* Serious adverse chemotherapy related adverse events (grade 3 or 4) that were symptomatic and required prolong chemotherapy break (\\>6weeks).\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the study subject's best interest to participate, in the opinion of the treating investigator.",{"count":119,"type":21},48,[121],"NA","To learn if circulating tumor DNA (ctDNA) testing before cytoreductive surgery (CRS) with or without heated intraperitoneal chemotherapy (HIPEC) can show if patients have a low or high risk of the disease returning and help doctors decide if less or more intense chemotherapy is needed as treatment before surgery. ctDNA testing measures the amount of tumor DNA (genetic information) in the blood.",[30,124],"Colorectal","2026-05-14",{"date":127,"type":41},"2026-05-18",{"date":129,"type":41},"2023-12-04",{"date":131,"type":21},"2027-04-30",{"name":75,"class":48},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":141,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":144,"conditions":145,"keywords":159,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":49},"100495686","genetics-of-appendix-cancer-study-100495686","NCT05734430","Genetics of Appendix Cancer Study","Genetics of Appendix Cancer: The GAP Study","GAP","Inclusion Criteria:\n\nGAP Social\n\n* Known diagnosis of appendix cancer in the United States\n* Mentally and physically able to consent and participate in the study\n\nGAP Vanderbilt\n\n* Known diagnosis of appendix cancer\n* Diagnosed by and\u002For consulting with a physician\u002Fclinical provider participating in the GAP Study\n* Mentally and physically able to consent and participate in the study\n\nGAP Parent\n\n* Biological parents (mother and\u002For father) of individuals actively participating in the GAP Study\n* Residing in the United States\n* Mentally and physically able to consent and participate in the study\n\nExclusion Criteria:\n\n* Women pregnant at the time of consent\n* Prisoners\n* Unable to provide informed consent\n* Unable to read, write, or complete questionnaires in English",true,{"count":143,"type":21},700,"The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix\u002Fappendiceal cancer who are ages 18+ years.",[146,88,147,148,30,149,150,151,152,153,154,155,156,157,158],"Appendix Cancer","Appendiceal Neoplasms","Appendiceal Mucinous Neoplasm","Appendiceal Carcinoid Tumor","Appendiceal Neoplasm Malignant Secondary","Appendix Adenocarcinoma","Appendix Mucinous Neoplasm","Appendix Tumor","Appendix Cancer Metastatic","Appendix NET","Low-Grade Appendix Mucinous Neoplasm","High Grade Appendix Mucinous Neoplasm","High Grade Appendix Mucinous Adenocarcinoma",[160],"Genetics","2025-04-15",{"date":163,"type":41},"2025-04-18",{"date":165,"type":41},"2022-11-11",{"date":167,"type":21},"2034-11",{"name":169,"class":48},"Andreana Holowatyj, PhD, MSCI"]